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Abstract
SARS-CoV-2 infection or COVID-19, currently regarded as ‘terror’ worldwide,
has spread uncontrollably as a serious menace. Till date, limited effective medicines
or treatments are available. The mortality and morbidity rates have increased
considerably, which have been aggravated by acute respiratory distress syndrome
(ARDS) and new and old cardiovascular injuries. To control COVID-19, many
drugs have been taken into consideration, like ACE2 blockers, anti-inflammatory
drugs, antibodies against IL-1 and anti-IL-6, Remdesivir, Dexamethasone,
Hydroxychloroquine and vaccines. In this chapter, preference is given to
Tocilizumab with the latest status of clinical research update available. Despite
several clinical research attempts, some have yielded promising results, others are
inconclusive.
Keywords: COVID-19, Tocilizumab, Clinical Studies, Antiviral drugs,
Public Health
1. Introduction
Since December 2019, the outbreak of the novel coronavirus (SARS-CoV-2)
infection (i.e. COVID-19), from Wuhan, China as a pandemic, has posed a serious
threat towards mankind, treatment of which is still unknown [1]. In Jan 30, 2020,
the novel coronavirus disease 2019 (COVID-19), was declared as the Sixth public
health emergency epidemic by the World Health Organization [WHO] [2]. Till date
there is no single drug to control it. Despite Remdesivir being used extensively for
the treatment, it is still under clinical trials [3] and not beyond question [4]. The
elderly, immune-compromised or people having co-morbidities led to acute
respiratory distress syndrome (ARDS), cardiovascular (CV) complications, and
multi-organ failure [2, 5]. Common symptoms of the disease include fever, cough,
myalgia, malaise, breathlessness and diarrhea [2]. Tocilizumab (a humanized anti-
IL-6 receptor antibody) is one of drugs used for the treatment of COVID-19 hospi-
talized patients [6]. This article summarizes all critical clinical trials to evaluate the
efficacy of Tocilizumab.
2. About the molecule
Tocilizumab is an Interleukin-6 Receptor Inhibitor, having a molecular formula
of [C6428H9976N1720O2018S42]. Its molecular mass is of [145.0 kDa], CAS num-
ber: [375823-41-9]. It is a recombinant humanized monoclonal antibody used in the
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treatment of inflammatory and autoimmune conditions like Rheumatoid arthritis,
multiple myeloma and prostate cancer, nowadays used extensively for COVID-19
treatment [7–11].
3. Tocilizumab as drug
Tocilizumab, an immunosuppressive monoclonal antibody drug having the tra-
ditional name Actemra and Atlizumab, has been reported to be effective against
COVID-19 in several countries such as China, France, Italy, Switzerland and Qatar
Xiaoling [12, 13]. The drug is known to treat patients with hyperinflammatory
syndrome and acute respiratory failure [14]. The drug is sold in the European Union
(EU) under the trade name RoActemra and in the United States as Actemra [15, 16].
The drug was first approved in 2005 as an orphan drug in Japan, used in the
treatment of Castleman’s disease [17]. Nowadays, Tocilizumab has acquired license
for EU, to be used alone or in combination with DMARDs [disease-modifying anti-
rheumatic drugs]. This combined therapy is used in the treatment of rheumatic
arthritis in adults, systemic form of juvenile idiopathic arthritis (sJIA) in children
above 2 years and with the polyarticular form of juvenile idiopathic arthritis (pJIA)
in children more than 2 years of age [17]. This drug displays a long elimination half-
life. Several studies were conducted to find out whether the drug is useful or not.
In a single centre study in Brescia [Italy], having an gathering of 100 patients,
8 mg/kg [max 800 mg] of the drug was advised to be given to patients by two
consecutive intravenous infusions 12 hr. apart. Significant clinical improvement
was observed in this case [18]. In another study by Alattar et al. [19] at Quatar, 25
patients having COVID-19 were administered with Tocilizumab, one to three
median doses of the drug individually [4.8 mg/kg]. Tocilizumab was associated
with dramatic decline in inflammatory markers, radiological improvement and
reduced ventilatory support requirements [19]. In a 61-year-old man with COVID-
19 symptoms, with a history of kidney transplantation, 324 mg Tocilizumab was
administered via subcutaneous route along with hydroxychloroquine that helped in
prevention of the disease and did not require mechanical ventilation [20]. However,
contrary reports do exist, that reports that Tocilizumab was not effective for
preventing intubation or death in moderately ill hospitalized patients with COVID-
19 [21].
4. USFDA approval
The drug Actemra (tocilizumab, Genentech, Inc., South San Francisco, CA) was
approved by USFDA to be used for the treatment of Rheumatoid Arthritis (RA),
Giant Cell Arthritis (GCA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Sys-
temic Juvenile Idiopathic Arthritis (SJIA) and Cytokine Release Syndrome (CRS)
[22]. However, despite of recommendation of NIH on usage of Tocilizumab for
COVID-19 treatment, it has not yet received approval of USFDA.
5. Dosage of tocilizumab for COVID-19 treatment
The use of Tocilizumab is recommended as per the US NIH guidelines only for
clinical trial studies [23]. The preference is mainly given to hospitalized patients
with increasing oxygen demand with or without elevated markers of systemic
inflammation. As per the recommendations, Tocilizumab (single intravenous [IV]
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dose of tocilizumab 8 mg/kg actual body weight up to 800 mg) in combination with
dexamethasone (6 mg daily for up to 10 days) is advised to be administered in
certain hospitalized patients experiencing rapid respiratory decompensation due to
COVID-19 [24].
6. Storage
This drug should be stored refrigerated at 2 to 8° C (36 to 46 F).
7. Plausible mechanism of tocilizumab against COVID-19
According to a study, by the team of Haiming Wei [25], after the SARS-CoV-2
infection, CD4 + T lymphocytes are activated to become pathogenic T helper cells,
generating GM-CSF (Granulo Macrophage Colony Stimulating Factor]. This leads
to severe inflammatory storm created by CD14 + CD16+ inflammatory monocytes
with elevated expression of IL-6. These excessive immune cells usually invade the
pulmonary circulation and cause damage to the immune system, thus leading to
functional disability of lungs and mortality. Therefore, drugs like Tocilizumab are
administered to prevent the cytokine storm. Tocilizumab has yielded effective
results as an IL-6R antagonist.
Excessive stimulation of IL-6 can cause CRS [Cytokine Release Syndrome] in
hospitalized patients. The higher the level of CRS, higher is the serum peak con-
centration of IL-6. IL-6 binds to its receptor IL-6R and a complex is formed. IL-6R
then binds to the signal transducer glycoprotein 130 (gp-130) to cause signal trans-
duction. Two types of IL-6R are there, one is the Soluble form (sIL-6R) and the
other is Membrane bound form [mIl-6R]. In classical signal transduction pathway,
IL-6 binds to mIL-6R [transmembrane integral protein], and forms a complex,
which then prohibits the connection of IL-6R with gp130 [integral membrane
protein]. Thus no cytokine storm is produced. In the trans-signaling pathway,
binding of Tocilizumab to sIl-6R, prevents the binding of IL-6R to gp130
[present on the membrane of monocytes, macrophages, dendritic cells] and
thus hinders release of inflammatory storm. JAK/STAT tyrosine kinase system
mediates one pathway, while Ras/mitogen-activated protein kinase (MAPK)/
NF-κB-IL-6 pathway mediates the other. Tocilizumab [humanized anti-IL-6R
monoclonal antibody], is thus considered a potential drug in COVID-19 treatment
[26, 27].
8. Other clinical considerations
Tocilizumab is contraindicated in immunocompromised individuals,
those who use biologic immunomodulating drugs, and in patients having
alanine aminotransferase >5 times the upper limit of normal; patients with
gastrointestinal perforation; those having uncontrolled serious bacterial, fungal,
or non-SARS-CoV-2 viral infection; absolute neutrophil count <500 cells/μL;
platelet count <50,000 cells/μL. The drug should also be avoided in individuals
having a known hypersensitivity to it [28]. It has been recommended to
administer Dexamethasone [or an alternative corticosteroid of dosage equal to
dexamethasone 6 mg] simultaneously in patients receiving Tocilizumab [9].
A patient’s clinical response to dexamethasone is initially accessed before
administering Tocilizumab [29]. The combination therapy yields an adverse
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effect in the form of severe and disseminated strongyloidiasis infestation.
Therefore, Ivermectin should be used as a prophylactic treatment [30].
9. Side effects
The common side effects include respiratory tract infections, headache, hyper-
tension, elevation in liver test. Rashes, erythema, oedema, itching can occur at the
infection site [31]. Tuberculosis, sepsis and fungal infection are the associated
infections that can occur. Hypersensitivity reactions, cancer, reactivation of herpes
zoster, gastrointestinal perforation in patients with diverticulitis are also seen in
some patients, though not significant [32].
10. Clinical trial status
The process of systemic review was followed and effectiveness of the drug
analyzed from the NIH, US National Library of Medicine Clinical Trial Registry
(ClinicalTrials.gov). At present (till May 2021), 81 clinical studies could be traced in
the name Toclilizumab [until May 2021]. 33 studies have been excluded due to non-
relevance. 48 records are included in this study. Some of the studies have yielded
promising initial results yet require more time for validation and declared to be
effective or safe. Among the 48 trials done on Tocilizumab, 17 are in Recruiting
stage, 12 trials have been concluded, 5 have been terminated, 1 has been withdrawn,
5 trials are in not yet recruiting stage and 6 are active but non recruiting. 1 among
the 47 trials is in phase 1, 16 trials are in phase 2, 14 are in phase 3 trial. Analyzing
the clinical trials from Table 1, it is evident that there is attempt to use Toclizumab
alone or in combination with other drugs looks promising for the treatment of
COVID 19 (Figure 1).
11. Comparing tocilizumab with other drugs involved in COVID-19
treatment
Several drugs employed for the treatment of COVID-19 through clinical trials
are: Remdesivir, Tocilizumab, Baricitinib, Sarilumab and Hydroxychloroquine. In
terms of clinical research output Remdesivir emerges as frontrunner, while
Tocilizumab may be considered as a potential drug candidate against COVID-19.
Despite the initial attempt of drug repurposing by using Hydroxychloroquine to
treat COVID-19, there were limited encouraging results for which, its administra-
tion was removed from the line of treatment in various countries. A comparison
between Tocilizumab and other drugs involved in the treatment of COVID-19 is
presented in Table 2.
12. Summarizing prominent publications on tocilizumab related to
COVID treatment
Apart from several clinical research outcomes (summarized in Table 1) there
has been several publications revealing scientific information on the mechanism,
application and prospect of the drug candidate Tocilizumab for COVID-19 treat-
ment. There are more than 30 publications found in PubMed (https://pubmed.ncbi.
nlm.nih.gov/) in the year 2021 among which few significant ones are summarized in
following Table 3.
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Status of clinical trials and stage: tocilizumab.
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Title of publication Significant observation Reference
1 2020 Tocilizumab in patients
hospitalized with Covid-19
Pneumonia
This trial consisted of more than 25%
of the patients who were older than
65 years of age, more than 75%
having at least one coexisting disease
condition, and greater than 80%
were in a minority racial or ethnic
group. Scientists found that the
possibility of progression to
mechanical ventilation or death by
day 28 was considerably lower among
patients who received tocilizumab
plus standard care in comparison to
those who received placebo plus
standard care.
[148]
2 2020 Tocilizumab in patients with
severe COVID-19: a
retrospective cohort study
This trial consisted of 1351 patients
who were admitted to the recruiting
centres. 544 (40%) patients with
severe pneumonia were also taken
into consideration. There were 359
(66%) male patients, with a median
age of 67 years. Tocilizumab
[administered intravenously or
subcutaneously] plus standard care
could reduce the mortality rate or
curb the usage of mechanical
ventilation in severe COVID-19
patients compared to those who
received only standard care as per
shown in this study.
[149]
3 2020 Impact of tocilizumab
administration on mortality in
severe COVID-19.
In this trial 84 patients were
administered with tocilizumab and
190 patients were not treated with
tocilizumab. Scientists could not
predict or conclude any favorable
outcome from this trial.
[150]
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Title of publication Significant observation Reference
4 2020 Why Tocilizumab could an
effective treatment for severe
COVID-19?
The IL-6 antagonist, Tocilizumab is
highly recommended by scientists to
curb the mortality of severe COVID-
19. Scientists hope this drug could be
beneficial in curbing the severity of
COVID-19 pandemic. This study
analyses the beneficial effects of this
drug.
[151]
5 2020 Effective treatment of severe
COVID-19 patients with
Tocilizumab.
The average age of the subjects in this
study were 56.8  16.5 y and ranged
from 25 to 88 years. Out of them in 21
patients, improvement of the rate of
deterioration of COVID-19 patients
was observed by scientists, which
suggested that this drug could be
effective enough to treat patients
with COVID-19.
[152]
6 2020 Hydroxychloroquine and
tocilizumab therapy in COVID-
19 patients- An observational
study.
In this retrospective observational
cohort study consisting of 2512
patients hospitalized COVID-19
patients, within a 13- hospital
network, scientists could not predict
any favorable outcome. On the
contrary, the use of Tocilizumab
alone yielded effective results,
that is, it helped in reducing the
death rate.
[153]
7 2020 Time to Reassess Tocilizumab’s
Role in COVID-19 Pneumonia.
The efficacy of the drug was unclear
from this study compared to other
observational studies.
[154]
8 2021 Tocilizumab in COVID-19:
some clarity amid controversy.
The recovery trial showed some
evidence regarding the use of
Tocilizumab in COVID-19 patients.
Scientists found that only 31% of the
population receiving Tocilizumab
showed promises of recovery as
compared to those receiving placebo.
Still, this drug therapy needs to be
combined with other drugs for better
outcomes.
[155]
9 2021 Effectiveness of Tocilizumab in
patients hospitalized with
COVID-19.
Scientists found that Tocilizumab
may be effective in diminishing the
health hazards of patients with
moderate to severe COVID-19 –
associated pneumonia and elevated
CRP level. Yet it needs to be
administered to a large mass to
fathom its efficacy.
[156]
10 2021 Tocilizumab in hospitalized
patients with severe Covid-19
Pneumonia.
Scientists could not gather any
significant clinical status or
predict any lowering of mortality




Prominent publications reporting the treatment of COVID-19 using Tocilizumab.
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13. Conclusion
Although the drug Tocilizumab has shown to reduce mortality and morbidity,
still it cannot be referred to as an anti-COVID drug and may only be effective in
patients having inflammation and lung damage caused by the coronavirus. More-
over the sensitivity of the drug limits its usage to a specific age and certain patients.
Moreover, Tocilizumab is not-yet approved by the USFDA. This drug brings a ray
of hope, as it’s very much effective in mitigating immune damage, lung functional
injuries and arterial oxygen saturation. Scientists therefore hope that this drug could
be beneficial to a large mass of population in diminishing the adverse effects of the
pandemic.
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